Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma  

作　　者：Tiantao Gao Xinghong Liu Qi Shen Zhu Luo Ping Feng Jia Miao Li Zheng Donglin Chen Jin Xiang 

机构地区：[1]Clinical Trial Center,West China Hospital of Sichuan University,Chengdu,Sichuan 610041,China [2]Department of Medicinal Natural Products,West China School of Pharmacy,Sichuan University,Chengdu,Sichuan 610041,China

出　　处：《Chinese Medical Journal》2022年第2期250-252,共3页中华医学杂志（英文版）

基　　金：The research was supported by the National Science and Technology Major Project of China(No.2017ZX09304023);the Major Specific Project of Sichuan Province(No.2020YFS0034).

摘　　要：To the Editor:Multiple myeloma(MM)is currently considered to be an incurable neoplasm and a systemic disease,and the first line of treatment plays a crucial role in MM patients,since the majority of patients do not survive beyond the first-line treatment.[1]Lenalidomide,a first-line drug in the treatment of MM,is sold as a capsule under the trade name Revlimid®,which is in great demand for an increasing incidence of MM.

关 键 词：patients MYELOMA CAPSULE 

分 类 号：R733.3[医药卫生—肿瘤] R969.1[医药卫生—临床医学]